Ignite Creation Date:
2024-05-05 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00147537
Status:
COMPLETED
Last Update Posted:
2013-10-30
First Post:
2005-09-02
Brief Title:
Combination Study Of CP-751871 With Paclitaxel And Carboplatin In Advanced Lung Cancer
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A Phase 1b Dose EscalationPhase 2 Randomized Non-Comparative Multiple Center Open Label Study Of CP 751871 In Combination With Paclitaxel And Carboplatin And Of Paclitaxel And Carboplatin Alone As First Line Treatment For Advanced Non-Small Cell Lung Cancer
Status:
COMPLETED
Status Verified Date:
2013-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Phase 1b Dose ExcalationExpansion Identify and characterize safety and tolerability of recommended phase 2 dose of CP-751871 when administered with paclitaxel and carboplatin Phase 1b Erlotinib Extension To characterize the safety and tolerability of CP751871 when administered with paclitaxel carboplatin and erlotinib
Phase 2 To test the efficacy of CP-751871 combined with paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer
Phase 2 To test the efficacy of CP-751871 combined with paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None